Opko Health Acquires Next Generation Prostate Cancer Tests | IVD Technology

Links shared publicly online about this topic.

0
total visits

Opko Health Acquires Next Generation Prostate Cancer Tests | IVD Technology

Opko Health Inc. announced the acquisition of an exclusive license from Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%. These novel biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York.

View full resource at ivdtechnology.com

Tags: Cancer, Prostate Cancer, Prostate, Healthy Living, Men's Health, Relationship, Biopsy